Key Players
Competitive Landscape
Four supplier models compete in the chronic myelomonocytic leukemia market: labeled hypomethylating therapy owners and diversified hematology groups alongside mutation-directed developers and exact-CMML biotechnology specialists.
Investment has moved in two directions since 2025: exact-CMML clinical assets and late-stage registration programs. Solu Therapeutics closed a USD 41 million Series A and dosed the first STX-0712 patient in April 2025. ImmuneOnco completed planned enrollment of 173 patients in its Phase III timdarpacept trial in July 2026. Treatment centers compare direct CMML evidence with administration burden and biomarker fit during formulary review. Price influences final selection among candidates with comparable clinical positions and workable delivery requirements for treatment centers.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| ImmuneOnco completed planned enrollment of 173 patients in its Phase III timdarpacept plus azacitidine trial in July 2026. | Treatment centers require controlled first-line CMML evidence to replace established hypomethylating pathways across routine specialist practice. | Exact-CMML programs are advancing from early studies toward registration-scale clinical evidence within rare-disease development portfolios. | Successful registration provides a route to first-line product revenue and hospital adoption across regulated markets with established specialist pathways. |
| Solu Therapeutics closed a USD 41 million Series A and dosed the first STX-0712 patient in April 2025. | Sponsors need sufficient capital and specialist sites to recruit small molecularly defined CMML populations across dispersed referral networks. | Venture financing is moving toward therapies designed around exact CMML biology and defined patient selection criteria. | CCR2-directed treatment addresses patients needing biologically targeted options beyond established hypomethylating regimens following specialist assessment. |
| Taiho Oncology received FDA orphan designation for co-packaged azacitidine and cedazuridine in CMML in February 2025. | Developers seek regulatory incentives that offset small patient pools and costly evidence generation across multicenter rare-disease programs. | Established hypomethylating platforms are being reformulated around oral or combined treatment routes for continuing specialist care. | A differentiated package provides recurring therapy revenue among eligible non-transplant patients across regulated healthcare systems. |
Bristol Myers Squibb, AbbVie, Roche, Incyte and Jazz Pharmaceuticals compete through labeled therapy or active myeloid programs without a qualifying exact-CMML development during this period.
Source: Future Market Insights, Chronic Myelomonocytic Leukemia Market and Myelodysplastic Syndrome Treatment Market Reports, 2026-2036.
Taiho Oncology and Bristol Myers Squibb cover oral and injectable hypomethylating therapy, while Solu and ImmuneOnco extend exact-CMML development through CCR2 and CD47 programs.
Who leads the chronic myelomonocytic leukemia market?
Taiho Oncology has the broadest documented direct position in this company set through FDA-approved oral INQOVI for CMML and continuing development around its hypomethylating platform. Bristol Myers Squibb competes through injectable VIDAZA, which remains embedded in hospital-led CMML treatment pathways.
Which developers hold documented CMML regulatory designations?
Solu Therapeutics received FDA Fast Track designation for STX-0712 in May 2026 and advances an exact-CMML Phase I program. ImmuneOnco reports FDA orphan designation for timdarpacept in CMML and advances a completed-enrollment Phase III program.
Which companies provide oral or injectable hypomethylating therapies?
Taiho Oncology provides oral decitabine-cedazuridine through INQOVI under a labeled myelodysplastic syndrome indication that includes eligible adults with CMML. Bristol Myers Squibb provides injectable azacitidine through VIDAZA for defined myelodysplastic syndrome populations that include CMML.
Which suppliers serve North America and Europe?
Taiho Oncology and Bristol Myers Squibb support labeled CMML pathways in North American and European healthcare systems. AbbVie and Roche add clinical study coverage across selected centers in France and the United States. Incyte, Jazz and Syndax contribute exact-CMML or transformation-stage programs through active studies in the United States and Europe.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Taiho Oncology, Inc. | United States and Canada | INQOVI oral hypomethylating therapy with FDA-approved CMML labeling. |
| Bristol Myers Squibb | United States and Europe | VIDAZA injectable azacitidine with a labeled CMML treatment pathway. |
| AbbVie Inc. | France and United States | Venetoclax combination studies involving higher-risk or post-HMA CMML. |
| F. Hoffmann-La Roche Ltd. | United States | Cobimetinib study for RAS-pathway-mutated CMML; investigational exact-market scope. |
| Incyte Corporation | United States | Ruxolitinib and axatilimab-ruxolitinib programs that include exact CMML populations. |
| ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | China with international patent coverage | Timdarpacept plus azacitidine Phase III program for treatment-naive CMML. |
| Solu Therapeutics, Inc. | United States | STX-0712 Phase I program for CMML and CCR2-directed development. |
| Kura Oncology, Inc. | United States and Japan | KOMZIFTI for NPM1-mutated AML; adjacent transformation-stage scope. |
| Jazz Pharmaceuticals plc | United States and Europe | CPX-351 study includes high-risk MDS or CMML; investigational myeloid scope. |
| Syndax Pharmaceuticals, Inc. | United States | Axatilimab-ruxolitinib study includes CMML; REVUFORJ serves transformation-stage AML. |
Research Methodology
The companies presented here explain market structure and do not constitute a ranking of commercial performance. Inclusion requires current evidence of a CMML-labeled therapy, an exact-CMML clinical program or an adjacent transformation-stage product. Regulator databases and trial registries provide the core evidence, supported by company releases and public filings. Regulatory designations remain assigned to the named sponsor or product without group-level transfer during the assessment. The 42.0% treatment-type share represents FMI's estimate for the 2026 base year within this report.
